曲克芦丁脑蛋白水解物注射液治疗颅脑损伤患者的临床研究  

Clinical trial of troxerutin and cerebroprotein hydrolysate injection in the treatment of patients with craniocerebral injury

作　　者：刘利[1] 张桂香 夏武 雷艳青[1] 黄宇[1] LIU Li;ZHANG Gui-xiang;XIA Wu;LEI Yan-qing;HUANG Yu(Department of Pharmacy,Hunan Brain Hospital,Changsha 410000,Hunan Province,China)

机构地区：[1]湖南省脑科医院药学部,湖南长沙410000

出　　处：《中国临床药理学杂志》2020年第23期3896-3899,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察曲克芦丁脑蛋白水解物注射液对颅脑损伤患者凝血、血小板计数(PLT)及缺血修饰白蛋白(IMA)水平的影响。方法将146例颅脑损伤患者,通过随机数字法分为试验组73例和对照组73例。对照组静脉滴注胞磷胆碱钠氯化钠注射液,每次500 mg,每天1次。试验组静脉滴注曲克芦丁脑蛋白水解物注射液,每次400 mg,每天1次。2组患者均持续治疗2周。比较2组氧化应激、凝血功能、格拉斯哥昏迷量表(GCS)评分、格拉斯哥预后量表(GOS)评分以及用药安全性。结果治疗后,对照组和试验组丙二醛(MDA)水平分别为(4.37±0.72)和(3.33±0.76)nmol·mL^-1,超氧化物歧化酶(SOD)水平分别为(75.82±6.95)和(94.85±6.29)kU·L^-1,IMA水平分别为(64.78±10.68)和(52.76±8.46)μg·L^-1,纤维蛋白原(FBG)水平分别为(3.61±0.55)和(3.02±0.53)g·L^-1,D-二聚体(D-D)水平分别为(2.44±0.27)和(2.01±0.19)mg·L^-1,PLT水平分别为(71.66±8.05)×10^9/L和(58.94±7.89)×10^9/L,差异均有统计学意义(均P<0.05)。与对照组相比,试验组GCS、GOS评分显著降低(P<0.05)。治疗期间,试验组发生轻度皮疹1例,药物不良反应发生率为1.37%(1例/73例);对照组发生胃肠道反应4例、头痛3例、失眠2例,药物不良反应发生率为12.33%(9例/73例),差异有统计学意义(P<0.05)。结论曲克芦丁脑蛋白水解物注射液治疗颅脑损伤效果确切,可有效降低氧化应激损伤,改善凝血功能,进而提高患者预后。Objective To explore the effect of troxerutin and cerebroprotein hydrolysate injection on the levels of coagulation,platelet count(PLT)and ischemic modified albumin(IMA)in patients with craniocerebral injury.Methods A total of 146 patients with craniocerebral injury were divided into treatment group(73 cases)and control group(73 cases)by random number method.Control group was treated with the citicoline and sodium chloride injection,500 mg·time^-1 and 1 time·d^-1.Treatment group was treated with troxerutin and cerebroprotein hydrolysate injection,400 mg·time^-1,1 time·d^-1.The two groups were treated for 2 weeks.The oxidative stress,coagulation function,scores of Glasgow coma scale(GCS)and Glasgow preemptive scale(GOS)and drug safety were compared between the two groups.Results After treatment,the levels of malondialdehyde(MDA)in control group and treatment group were(4.37±0.72)and(3.33±0.76)nmol·mL^-1,the levels of superoxide dismutase(SOD)were(75.82±6.95)and(94.85±6.29)k U·L^-1,the levels of IMA were(64.78±10.68)and(52.76±8.46)μg·L^-1,the levels of fibrinogen(FBG)were(3.61±0.55)and(3.02±0.53)g·L^-1,the levels of D-dimer(D-D)were(2.44±0.27)and(2.01±0.19)mg·L^-1,the levels of PLT were(71.66±8.05)×10^9/L and(58.94±7.89)×10^9/L,all with statistical differences(all P<0.05).The GCS and GOS scores of treatment group were reduced,with statistical differences compared with control group(P<0.05).One patient in treatment group had a mild rash,the incidence of adverse drug reactions was1.37%(1 case/73 cases),which in control group was 12.33%(9 cases/73 cases),including gastrointestinal reactions(4 cases),headache(3 cases)and insomnia(2 cases),with significant difference(P<0.05).Conclusion The effect of troxerutin and cerebroprotein hydrolysate injection in the treatment of craniocerebral injury is accurate,the oxidative stress injury can be effectively reduced,the coagulation function can be improved,and the prognosis of the patient is optimized.

关 键 词：曲克芦丁脑蛋白水解物注射液 颅脑损伤 氧化应激 凝血功能 

分 类 号：R28[医药卫生—中药学]